GlassScriptPhysician profile
Joseph A Clemente
NPI 1326129586
$3,419.89
in general payments reported to CMS, 2019-2025
30 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,206 · 2020: $1,068 · 2021: $680 · 2022: $72.47 · 2023: $105 · 2024: $111 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $393.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $495.02 | 2019-2021 | |
| Amarin Pharma, INC. | $459.98 | 2019-2021 | |
| Allergan, INC. | $315.35 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $312.77 | 2019-2021 | |
| Astellas Pharma US INC | $300.02 | 2019-2025 | Veozah |
| Lilly USA, LLC | $237.88 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $215.38 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.47 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $130.94 | 2019-2021 | |
| Abbvie INC. | $126.46 | 2021 | |
| Intuitive Surgical, INC. | $91.42 | 2023 | |
| Pfizer INC. | $62.20 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $60.04 | 2019 | |
| Becton, Dickinson and Company | $57.55 | 2022 | |
| Amgen INC. | $51.70 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $38.92 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $38.59 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $37.60 | 2019-2021 | |
| Abbott Laboratories | $33.63 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Horizon Therapeutics Plc | $29.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $26.75 | 2019 | |
| Daiichi Sankyo INC. | $26.09 | 2019 | |
| Esperion Therapeutics, INC. | $25.30 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $23.84 | 2025 | |
| Glaxosmithkline, LLC. | $14.92 | 2022 | |
| Radius Health, INC. | $13.68 | 2019 | |
| Genentech USA, INC. | $13.50 | 2020 | |
| Arbor Pharmaceuticals, INC. | $13.00 | 2019 | |
| Eisai INC. | $12.96 | 2021 | |
| Sanofi Pasteur INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Clemente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.